drugset / Trial / NCT00612872

Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects

NCT00612872 ↗

Phase 1 Terminated 46 enrolled Institute for Neurodegenerative Disorders
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

To assess the dynamic uptake and washout of 123-I CLINDE, a potential imaging biomarker for inflammatory changes in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and subjects with Alzheimer (AD) or Parkinson disease (PD). To perform blood metabolite characterization of 123-I CLINDE in healthy and subjects with AD or PD to determine the nature of metabolites in assessment of 123-I CLINDE as a single photon computed tomography (SPECT) brain imaging agent. Evaluate the test/retest reproducibility of 123-I CLINDE, and SPECT in AD and PD subjects and healthy controls

Timeline

Start
2008-01
Primary completion
2009-11-01
Completion
2009-11-01

Outcome

Outcome not reported

Stopped: “Results did not show reason to continue with study.”

Drugs

EvaluationDrugModalityDoseRoute
Subject CLINDE Diagnostic / imaging agent 185 mbq Other